

## Meeting Agenda

|               |                                                                                                                                                                                                                                                                                                                            |      |                 |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------------|
| Division      | Iowa Medicaid Quality Improvement Organization (QIO)                                                                                                                                                                                                                                                                       |      |                 |
| Meeting Title | Clinical Advisory Committee (CAC)                                                                                                                                                                                                                                                                                          |      |                 |
| CAC Chair     | Bill Jagiello, DO                                                                                                                                                                                                                                                                                                          |      |                 |
| Facilitator   | Julie Riegel                                                                                                                                                                                                                                                                                                               |      |                 |
| Date          | July 17, 2026                                                                                                                                                                                                                                                                                                              | TIME | 1:00pm - 4:00pm |
| Location      | <p><u>Virtual: Via Zoom:</u><br/> <a href="https://telligent.zoom.us/meeting/register/Zy-MrAZjRc-j_qcidl_J6w">https://telligent.zoom.us/meeting/register/Zy-MrAZjRc-j_qcidl_J6w</a></p> <p><u>In-Person:</u><br/>           Lucas Building Capitol Complex, 321 E 12<sup>th</sup> St, Des Moines, Conference Room L221</p> |      |                 |

## Meeting Objectives

The purpose of the CAC is to increase the efficiency, quality, and effectiveness of the Medicaid healthcare system. The CAC provides a process for physician and other healthcare provider contributions to promote quality care, member safety, cost effectiveness, and positive physician and provider relations through discussion about Medicaid benefits and healthcare services.

The CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decisions to the Department of Health and Human Services (HHS) for the Iowa Medicaid program.

**HIPAA Reminder:** As a reminder to all members of the public who are presenting during the CAC meeting: Do not provide any personal health information (PHI) regarding a member covered by Iowa Medicaid Insurance that would constitute a violation of Federal HIPAA standards.

## Meeting Participants

|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Iowa Medicaid     | <input checked="" type="checkbox"/> Michael Line, MD, HHS Chief Medical Officer<br><input type="checkbox"/> Rebecca Curtiss, HHS Deputy Director of Operations<br><input type="checkbox"/> Jenny Erdman, HHS Quality, Innovation & Medical Policy Bureau Chief<br><input type="checkbox"/> Andrea Maher, HHS LTSS Bureau Chief<br><input type="checkbox"/> Tami Lichtenberg, QIO Director<br><input checked="" type="checkbox"/> Bill Jagiello, DO, QIO<br><input checked="" type="checkbox"/> Else Umbreit, PharmD, QIO                                                                                                                                                                                       |
| Committee Members | <input checked="" type="checkbox"/> Dana Danley, MD, Family Practice<br><input checked="" type="checkbox"/> Diana Smith, ARNP-Family Practice<br><input checked="" type="checkbox"/> Chitra Reddy, MD, Endocrinology<br><input checked="" type="checkbox"/> Geetanjali Sahu, MD, Child and Adolescent Psychiatrist<br><input checked="" type="checkbox"/> Wendy Sanders, ARNP-Family Practice<br><input checked="" type="checkbox"/> Dawn Schwartz, ARNP- Neonatology/Pediatrics<br><input checked="" type="checkbox"/> Kelli Roenfan, DO, Family Medicine, OB/Gyn<br><input checked="" type="checkbox"/> Kaaren Olesen, DO, OB/Gyn<br><input checked="" type="checkbox"/> Seema Harichand-Herdt, MD, Oncology |



Managed Care  
Organizations

- ☐ Dr. Paul Mulhausen, Iowa Total Care
- ☐ Dr. Timothy Gutshall, Molina Healthcare of Iowa
- ☒ Dr. Jason Kessler, Wellpoint
- ☐ Dr. Jeff Chaffin, Delta Dental of Iowa
- ☒ Dr. Austin Voves, DentaQuest

## Agenda Topic

### Public Comment Period

- A maximum of 5 minutes will be allotted to each public guest who has submitted a completed [Conflict of Interest Disclosure](#). Submissions must be received no later than one week prior to the meeting date.
- To be respectful of the meeting time if you find your topic will exceed the maximum 5-minute allotment we welcome you to submit your detailed information to [CAC@hhs.iowa.gov](mailto:CAC@hhs.iowa.gov) prior to and/or post meeting.

### Announcements

- Recognition of Service: Dr. Dana Danley, MD, Family Practice
- Welcome: Dr. Seema Harichand-Herdt, MD, Oncology

### • Approval of April 17, 2026, Meeting Minutes

### New Business

#### Consent Agenda

#### Durable Medical Equipment (6):

1. Custom Knee Orthotics
2. Enteral Products and Supplies
3. Fractional Flow Reserve
4. High Frequency Chest Wall Oscillation
5. Medical Foods
6. Strollers and Wheelchairs for Safety

#### Surgical Procedures (5):

7. Laser Linear Accelerator Based Stereotactic Radiosurgery
8. Left Ventricular Assist Device
9. Lung Transplant
10. Reduction Mammoplasty/Mastopexy
11. Risk Reduction Mastectomy

#### Physician Administered Medications (10):

12. Adakveo (crizanlizumab-tmca)
13. Columvi (glofitamab-gxbm)
14. Fyarro (sirolimus protein-bound particles)
15. Jemperli (dostarlimab-gxly)
16. Namenda (memantine) for Autism Spectrum Disorder
17. Opdualag (nivolumab and relatlimab-rmbw)
18. Rylaze [asparaginase erwinia chrysanthemi (recombinant)-rywn]
19. Sarclisa (isatuximab-irfc)
20. Talvey (talquetamab-tgvs)
21. Zynlonta (loncastuximab tesirine-lpyl)



## Criteria Review

### Physician Administered Medications - Review (3):

1. Elrexio (elranatamab-bcmm)
2. Fasenra (benralizumab)
3. Monjuvi (tafasitamab-cxix)

### **Upcoming Meetings**

- Friday, October 16, 2026
  - o Virtual Meeting Link: [https://telligen.zoom.us/meeting/register/Zy-MrAZjRc-j\\_qcidl\\_J6w](https://telligen.zoom.us/meeting/register/Zy-MrAZjRc-j_qcidl_J6w)
- Friday, January 15, 2027
  - o Virtual Meeting Link: to be announced

### **Adjournment**

## Additional Information

- **Iowa Medicaid CAC contact:** [CAC@hhs.iowa.gov](mailto:CAC@hhs.iowa.gov)
- **Iowa Medicaid CAC webpage:** <https://hhs.iowa.gov/about/advisory-groups/clinical-advisory-committee-cac>
- **Iowa Medicaid Fee Schedules webpage:** <https://hhs.iowa.gov/programs/welcome-iowa-medicaid/policies-rules-and-regulations/covered-services-rates-and-payments/fee-schedules>
- **Guests wanting to speak during the public comment period must complete a [CAC Disclosure Form](#) and email it to [CAC@hhs.iowa.gov](mailto:CAC@hhs.iowa.gov).** Submissions must be received no later than one week prior to the meeting date.

### **Meeting Minutes (Q3 2026)**

**Opening:** Julie Riegel, Iowa Medicaid QIO, welcomed everyone to the quarterly Iowa Medicaid Clinical Advisory Committee (CAC) Meeting for 2026, and provided an overview of the house rules.

**Verbal Roll Call of the Committee Members:** Quorum was confirmed with 9 of 9 members.

**Introduction:** Due to technical difficulties, the meeting was delayed. Julie introduced Committee Chairman, Dr. Jagiello, who is the Medical Director for Iowa Medicaid, QIO. Julie presented the meeting objectives and the instructions for the public comment period presentations, with the use of a visible timer for each public guest speaker and allotment of 5 minutes to present.

#### **Announcements:**

1. **Recognition of Service, Dr. Dana Danley** - Dr. Jagiello announced that Dr. Danley's tenure was ending as a CAC member due to completing her two terms.
2. **Introduction of new CAC member:** Dr. Jagiello announced Dr. Seema Harichand-Herd, as a new Clinical Advisory Committee member.

**Approval of April 17, 2026, Minutes:** Dr. Jagiello asked if the committee members had any changes to the April meeting minutes, with no request for changes, he asked for a motion to approve the minutes from the Committee.

- First Motion to approve by Dawn Schwartz
- Second Motion to approve by Diana Smith

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley - Family Practice
- ☒ Diana Smith, ARNP - Family Practice
- ☒ Dr. Chitra Reddy - Endocrinology
- ☒ Dr. Geetanjali Sahu - Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP - Family Practice
- ☒ Dawn Schwartz, ARNP - Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfanz, Family Medicine, OB/Gyn
- ☒ Dr. Kaaren Olesen, OB/Gyn
- ☐ Dr. Seema Harichand-Herd, Oncology (abstained from voting due to new member)

#### **Consent Agenda:**

Julie Riegel provided the purpose of the Consent Agenda and explained the procedure for archiving criteria. Archival of criteria means the prior authorization requirements for the test or procedures are not going away, rather the criteria are being replaced by MCG Guidelines.

Dr. Jagiello asked the committee if there were any comments or questions about an item on the consent agenda, adding that a committee member may, at their request, take an item off the consent agenda and open it up for discussion. With no comments or questions heard, Dr. Jagiello asked for a motion to approve the consent agenda as presented.

- First Motion to approve by Dr. Dana Danley
- Second Motion to approve by Diana Smith

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley - Family Practice
- ☒ Diana Smith, ARNP - Family Practice
- ☒ Dr. Chitra Reddy - Endocrinology
- ☒ Dr. Geetanjali Sahu - Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP - Family Practice
- ☒ Dawn Schwartz, ARNP - Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfan, Family Medicine, OB/Gyn
- ☒ Dr. Kaaren Olesen, OB/Gyn
- ☒ Dr. Seema Harichand-Herdt, Oncology

### **Criteria Review:**

After the vote, Dr. Jagiello stated criteria for review consist of Physician Assisted Medications and Dr. Umbreit with the Iowa Medicaid Quality Improvement Organization would present.

Dr Umbreit announced that there were 3 medications on the Criteria Review to review.

#### **1. Elrexfio (elranatamab-bcmm)**

Dr. Umbreit presented the annual review for Elrexfio. Updated Overview, Criteria, and Approval Information and Quantity Limits to account for additional dosing regimen of 76 mg every 4 weeks, starting at week 49 and thereafter, for patients who have maintained the response following 24 weeks of treatment at the biweekly dosing schedule. Dosing schedule change approved by the FDA on 7/10/2025.

Dr. Jagiello thanked Dr. Umbreit and asked the committee if they had any questions or comments about the revised policy or criteria.

Hearing none he asked for a motion and a second to approve the revised criteria.

- First motion to approve by Diana Smith
- Second motion to approve Dawn Schwartz

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley - Family Practice
- ☒ Diana Smith, ARNP - Family Practice
- ☒ Dr. Chitra Reddy - Endocrinology
- ☒ Dr. Geetanjali Sahu - Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP - Family Practice
- ☒ Dawn Schwartz, ARNP - Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfan, Family Medicine, OB/Gyn
- ☒ Dr. Kaaren Olesen, OB/Gyn
- ☒ Dr. Seema Harichand-Herdt, Oncology

## 2. Fasenra (benralizumab)

Dr. Umbreit presented the annual review for Fasenra. Fasenra received a new indication for the treatment of adult and pediatric patients 12 years of age and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. This indication was approved by the U.S. Food and Drug Administration (FDA) on May 13, 2026.

Dr. Christine A. Dubé, B.S. PharmD, PAHM from AstraZeneca, was acknowledged by Dr. Jagiello, as a registered speaker. Dr. Jagiello asked if Dr. Dubé had any questions or comments regarding Dr. Umbreit's presentation. Dr. Dubé declined and yielded her speaking time back to the committee.

Dr. Jagiello thanked Dr. Umbreit and asked the committee if they had any questions or comments about the revised policy or criteria.

Hearing none he asked for a motion and a second to approve the revised criteria.

- First motion to approve by Diana Smith
- Second motion to approve Dawn Schwartz

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley - Family Practice
- ☒ Diana Smith, ARNP - Family Practice
- ☒ Dr. Chitra Reddy - Endocrinology
- ☒ Dr. Geetanjali Sahu - Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP - Family Practice
- ☒ Dawn Schwartz, ARNP - Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfanz, Family Medicine, OB/Gyn
- ☒ Dr. Kaaren Olesen, OB/Gyn
- ☒ Dr. Seema Harichand-Herdt, Oncology

## 3. Monjuvi (tafasitamab-cxix)

Dr. Umbreit presented the annual review for Monjuvi. Monjuvi received a new indication for treatment of relapsed or refractory follicular lymphoma (FL) in adult patients. This indication was approved by the U.S. Food and Drug Administration (FDA) on June 18, 2026.

Dr. Jagiello thanked Dr. Umbreit and asked the committee if they had any questions or comments about the revised policy or criteria. Hearing none he asked for a motion and a second to approve the revised criteria.

- First motion to approve by Diana Smith
- Second motion to approve Dr. Kaaren Oleson

Committee Member by roll call vote for approval:

- ☒ Dr. Dana Danley - Family Practice
- ☒ Diana Smith, ARNP - Family Practice
- ☒ Dr. Chitra Reddy - Endocrinology
- ☒ Dr. Geetanjali Sahu - Child and Adolescent Psychiatrist
- ☒ Wendy Sanders, ARNP - Family Practice
- ☒ Dawn Schwartz, ARNP - Neonatology/Pediatrics
- ☒ Dr. Kelli Roenfanz, Family Medicine, OB/Gyn
- ☒ Dr. Kaaren Olesen, OB/Gyn
- ☒ Dr. Seema Harichand-Herdt, Oncology

Julie Riegel thanked everyone for joining and welcomed everyone to join the upcoming Quarter 3 CAC meeting on October 16, 2026. The next meeting will be scheduled for January 15, 2027. Dr. Jagiello asked if there were any questions, hearing none asked for a motion to adjourn.

- First motion to adjourn by Dr. Harichand-Herdt
- Second motion to adjourn by Dawn Schwartz